इसराइल - हिब्रू - Ministry of Health

קיור מדיקל אנד טכניקל סופלאי - רופא - the valves are intended for the replacement of malfunctioning intracardiac valves.

इसराइल - हिब्रू - Ministry of Health

קיור מדיקל אנד טכניקל סופלאי - אחות - שקיות סטריליות חד פעמיות להזנה תוך ורידית

इसराइल - हिब्रू - Ministry of Health

עינת מדיקל סוכנויות בע"מ - רופא - עדשות תוך עיניות לניתוחי קטרקט

इसराइल - हिब्रू - Ministry of Health

j-c healthcare ltd. - כלל האוכלוסיה - contact lenses

इसराइल - हिब्रू - Ministry of Health

אלדן ציוד אלקטרוני בע"מ - צוות טכני - in vitro diagnostic kits for the detection and quantification of viral/bacterial dna/or rna

इसराइल - हिब्रू - Ministry of Health

קודן מדיקם ציוד רפואי והדרכה בע"מ - מומחה - ציוד רפואי סטרילי ולא סטרילי לפי דגמים מטה

इसराइल - हिब्रू - Ministry of Health

שטיינר הרמינה מכשירי שמיעה בע"מ - צוות טכני - המכשירים משמשים לבדיקות שמיעה וזיהוי ליקויים בשמיעה

इसराइल - हिब्रू - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

इसराइल - हिब्रू - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 2000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

इसराइल - हिब्रू - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 30000 iu / 0.75 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob